Current Hypertension Reviews最新文献

{"title":"WITHDRAWN: Hypertension and High-Density Lipoprotein Cholesterol: A Narrative Review","authors":"Rufei Liu, Wenli Cheng","doi":"10.2174/0115734021345634241115115253","DOIUrl":"10.2174/0115734021345634241115115253","url":null,"abstract":"<p><p>Since the authors are not responding to the editor’s requests to fulfill the editorial requirement, therefore, the article has been withdrawn.</p><p><p>Bentham Science apologizes to the readers of the journal for any inconvenience this may have caused.</p><p><p>The Bentham Editorial Policy on Article Withdrawal can be found at https://benthamscience.com/editorial-policies-main.php</p><p><strong>Bentham science disclaimer: </strong>It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. Furthermore, any data, illustration, structure or table that has been published elsewhere must be reported, and copyright permission for reproduction must be obtained. Plagiarism is strictly forbidden, and by submitting the article for publication the authors agree that the publishers have the legal right to take appropriate action against the authors, if plagiarism or fabricated information is discovered. By submitting a manuscript the authors agree that the copyright of their article is transferred to the publishers if and when the article is accepted for publication.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":""},"PeriodicalIF":0.8,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential Therapeutic Effects of Flavonoids in Cardiovascular Disorders: Review.","authors":"Sonia Singh, Ashima Ahuja, Mahima Varshney","doi":"10.2174/0115734021373759250730062326","DOIUrl":"10.2174/0115734021373759250730062326","url":null,"abstract":"<p><strong>Introduction: </strong>Flavonoids in various fruits and vegetables exert multifaceted biological effects. They are widely explored for cardiovascular, antitumor, antioxidant, antibacterial, antifungal, neuroprotective, and anti-inflammatory effects. Flavonoid cardioprotection is helpful in the management of myocardial injury, stroke, atherosclerosis, hypertension, and ischemia. Cardiovascular disease (CVD) has become a global threat in recent years due to increased mortality and morbidity rates. The increased mortality due to CVD among women, children, and poor economic groups has boosted the socio-economic burden on health care. Various researchers have explored the commercial applications of flavonoids, including quercetin, apigenin, luteolin, and catechin, as dietary supplements.</p><p><strong>Methods: </strong>The findings were searched in the Google Scholar, Scopus, PubMed, and PubChem databases.</p><p><strong>Results: </strong>Preclinical and clinical investigations have promoted the safety of flavonoids, such as apigenin and quercetin, for use as nutraceuticals that promote health. Flavonoids and their potential mechanisms of action and clinical applications offer insights for researchers and scientists to explore in the fields of medical and nanomedicine sciences. Nanomedicine, like liposomes, carbon nanotubes, nanosponges, and nanoparticles containing flavonoids, is used for its efficacy, potency, and target delivery.</p><p><strong>Discussion: </strong>Flavonols have the potential to regulate vasodilation and prevent apoptosis. Furthermore, their supplementation may reduce the risk of cardiovascular complications. Flavonoids function as antioxidants and exhibit potent anti-inflammatory effects by mediating inflammatory pathways, thereby contributing to the management of cardiovascular complications. Emerging evidence from researchers suggests flavonoids improve endothelial function and reduce blood pressure. Furthermore, flavonoids derived from cocoa, such as catechins, and those found in tea also enhance endothelial function. Nanosystems can enhance the solubility, permeability, and effectiveness of flavonoids as antioxidants, while also promoting controlled drug delivery. Nanoformulations can enhance the effects of morin, rutin, quercetin, and other flavonoids, significantly improving therapeutic outcomes.</p><p><strong>Conclusion: </strong>These findings offer researchers and scientists a novel technological approach utilizing flavonoids to address metabolic syndromes and related health conditions, thereby supporting personalized care and improving patient outcomes.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"195-208"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nanotechnology-Enhanced Transdermal Patches for Hypertension: A Review.","authors":"Nishant Yadav, Parveen Kumar, Thakur Gurjeet Singh, Sushma Devi","doi":"10.2174/0115734021373953250416105243","DOIUrl":"10.2174/0115734021373953250416105243","url":null,"abstract":"<p><p>Transdermal Drug Delivery System (TDDS) is one of the controlled drug delivery systems whose purpose is to deliver medication through the skin at a predetermined and regulated rate. Nanotechnology has enhanced the skin's absorption of lipophilic, low-molecular-weight medicines with low-dose efficacy, making transdermal drug delivery systems a viable technique for treating various conditions. TDDS permits greater skin permeation of hydrophilic drugs, and scientists are studying macromolecules to improve disease treatment and vaccine development. While additional study is needed to determine nanocarrier safety, this approach could increase the usage of transdermal routes for administering hypertension medicines. As hypertension remains the most prevalent form of cardiovascular illness, we focus on how nanoparticles as skin delivery methods might be used to better treat this global problem. In addition, patients may not be willing to comply with traditional doses due to the greater frequency of drug administration necessary for long-term care of hypertension conditions. Transdermal drug delivery has provided numerous benefits to the medical community since its inception. These benefits include the drug's non-invasive nature, extended therapeutic effect, reduced adverse effects, greater bioavailability, improved patient compliance, and simple termination. This review aims to explore the potential of several antihypertensive drugs for transdermal delivery.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"152-173"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144054345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding Efficacy of Using ACEIs and ARBs in Chronotherapeutic Treatment of Hypertension: Which Drug When?","authors":"Jasmine Yadav, Naim Khan, RIna Das, Dinesh Kumar Mehta","doi":"10.2174/0115734021332079241226115916","DOIUrl":"10.2174/0115734021332079241226115916","url":null,"abstract":"<p><p>Hypertension, a prevalent global health issue, poses significant risks for morbidity and mortality. The interplay between hypertension and comorbidities like diabetes and chronic kidney disease (CKD) underscores the urgency for effective management strategies. Chronotherapy, aligning medication administration with circadian rhythms, emerges as a promising approach to optimize treatment outcomes. The objective of this study is to assess the safety and efficacy of the use of ACEIs and ARBs in the chronotherapeutic treatment of hypertension. We aim to clarify the influence of circadian blood pressure patterns on the efficacy of medications and investigate the potential of chronotherapy in the management of hypertension by conducting a thorough examination of the existing literature. A literature search spanning from January 1980 to 2023 was conducted using PubMed, Scopus and Google Scholar databases. Search terms included ACE inhibitors, ARBs, chronotherapy, hypertension, and circadian rhythm of blood pressure. Studies investigating the effects of chronotherapy with ACEIs and ARBs in hypertensive patients were analyzed. Chronotherapy offers a personalized approach to hypertension management, leveraging the dynamic nature of circadian rhythms. By administering ACEIs or ARBs at night, the risk of morning blood pressure surges, associated with adverse cardiovascular events, can be mitigated. However, the optimal timing and combination of medications remain areas of ongoing research. Our review highlights the potential of chronotherapy with ACEIs and ARBs as a promising avenue for hypertension treatment. Further research is warranted to elucidate the mechanisms underlying circadian blood pressure regulation and optimize chronotherapeutic strategies. This comprehensive evaluation underscores the need for personalized treatment approaches tailored to individual circadian rhythms for improved hypertension management and reduced cardiovascular risk.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"15-30"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Pediatric Hypertension: Mechanism Insights, Clinical Trials and Innovation.","authors":"Monika Verma, Smita Narwal, Gurvirender Singh, Nisha Grewal, Neha Yadav, Dushyant, Ashwani K Dhingra","doi":"10.2174/0115734021400792250807110550","DOIUrl":"10.2174/0115734021400792250807110550","url":null,"abstract":"<p><p>Pediatric hypertension (PH) is an emerging global public health issue, increasingly linked to genetic, environmental, and lifestyle factors. Early-onset hypertension is associated with progressive long-term cardiovascular problems. This overview outlines the epidemiology, etiology, pathophysiology, treatment modalities, and current clinical studies related to hypertension in children and adolescents. A methodical search was conducted on PubMed, Scopus, and Web of Science using specific preset keywords. Recent high-quality peer-reviewed studies, trials, and reviews from the past decade were highlighted. The primary factors are genetic predisposition, renal artery stenosis, activation of the renin-angiotensin-aldosterone system (RAAS), obesity, metabolic syndrome, and sodium excess. Treatment involves lifestyle modifications and pharmacological intervention with ACE inhibitors, calcium channel blockers, beta-blockers, and diuretics. Recent clinical trials have provided insights into the safety and efficacy of therapies. The effective management of pediatric hypertension relies on prompt identification and individualized treatment. In future studies, priority should be given to precision medicine, long-term follow-up data, and the utilization of technological resources for surveillance.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"217-230"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of Non-Adherence to Antihypertensive Medication in India: A Systematic Review and Meta-Analysis of 18,808 Hypertensive Patients.","authors":"Mokanpally Sandeep, M Surya Durga Prasad, Sree Sudha Tanguturi Yella, Muhammad Aaqib Shamim, B R Shamanna, Dandge Shailendra","doi":"10.2174/0115734021377630250903105143","DOIUrl":"10.2174/0115734021377630250903105143","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension is a major contributor to disability-adjusted life years (DALYs) worldwide, as highlighted by the Global Burden of Disease study (GBD 2021). Effective management of hypertension through medication can significantly lower the risks associated with the condition. It is important to recognize that not adhering to antihypertensive therapy often leads to negative health outcomes.</p><p><strong>Methods: </strong>We conducted a thorough search of databases such as \"Embase, PubMed, Web of Science, Cochrane Library, EBSCOHost, and Scopus\" from their inception up to December 4th, 2023. This search focused on studies involving patients with hypertension. Our review specifically targeted studies conducted in India, published in English, and focused on the prevalence of non-adherence to antihypertensive medication. We used a random-effects model to pool the findings and assessed heterogeneity using the I² statistic, with a significance level set at p < 0.05. Subgroup analyses were performed to identify areas with a higher prevalence. This review was prospectively registered in PROSPERO (CRD42024489527).</p><p><strong>Results: </strong>This review included 40 studies from India, encompassing 18,808 patients with hypertension. The pooled prevalence of non-adherence to antihypertensive medication was 48% (95% CI 39%-56%, PI = 9%-90%), with a high degree of heterogeneity (I2=98%). Meta-regression showed that non-adherence was linked to younger age (p<0.01). Subgroup analysis revealed a varying prevalence across India, with the eastern region showing the highest prevalence at 76% (95% CI 31%-96%), followed by the order East > North > West > South (p < 0.01). A higher prevalence was also observed in community settings (51%) and rural areas (57%).</p><p><strong>Discussion: </strong>Findings of this study shed light on the growing prevalence of nonadherence to antihypertensive medication among Indian hypertensive patients. Nonadherence patterns vary across settings and contexts, reinforcing the need for more longitudinal studies and context-specific targeted interventions. Subgroup analyses revealed no significant reduction in heterogeneity, highlighting the need for more qualitative studies.</p><p><strong>Conclusion: </strong>Given the high and regionally variable prevalence of non-adherence to antihypertensive medication in India, it is crucial to develop localized strategies to improve adherence to hypertension treatment.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"231-246"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145030939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preface.","authors":"Guido Grassi","doi":"10.2174/0115734021411011250501112641","DOIUrl":"10.2174/0115734021411011250501112641","url":null,"abstract":"","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"63"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144024426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of New Symmetrical and Asymmetrical 1,4-dihydropyridine Derivatives as Potential Antihypertensive Agents: An <i>In silico</i> Evaluation.","authors":"Ruhani Raj, Charu Parjapati, Minakshi Garg, Anupreet Kaur","doi":"10.2174/0115734021328359241206073629","DOIUrl":"10.2174/0115734021328359241206073629","url":null,"abstract":"<p><strong>Introduction: </strong>Hypertension is a worldwide problem that affects people of all ethnicities and social groups. Its mortality rate has been steadily increasing. However, several pharmacological compounds have been used to manage hypertension and related issues. Calcium Channel Blockers (CCBs) based on Dihydropyridine (DHP) are used as first-line therapy. It is well established that simple adjustments to an existing medicine's fundamental structure can considerably improve its efficacy.</p><p><strong>Materials and methods: </strong>The purpose of this research study was to create potential antihypertensive drugs utilizing a 1,4-DHP scaffold and analyze their binding processes with different calcium channel proteins for comparative analysis, with PDB IDs 3LV3, 1T0J, and 6DAF. This study used molecular docking and ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) profiling to predict the binding efficacy of newly produced potential drugs, such as CCBs.</p><p><strong>Results: </strong>The binding energy of the protein with the newly created compounds ranged between -2.6 and -7.26 kcal/mol (3LV3), -7.42 to -10.36 kcal/mol (1T0J), and -6.63 to -11.98 kcal/mol (6DAF).</p><p><strong>Discussion: </strong>The predicted ADMET profiling yielded significant results, indicating that among the virtually prepared ligands, apart from the standard drugs amlodipine and nifedipine, ligand numbers 60 and 13 showed a favorable ADMET profile.</p><p><strong>Conclusion: </strong>In this study, drug development efforts focused on modifying existing hypertension medications through <i>in silico</i> analysis. From hundreds of synthesized ligands, 19 showed optimal docking scores. ADMET profiling of these 19 ligands revealed ligands 60 and 13 to have favorable profiles. The Swiss ADME and ADMET lab 2.0 tools confirmed these findings, highlighting their potential for further development.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"45-61"},"PeriodicalIF":1.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142839998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Dose-response of Blood Pressure Variability in Stroke and Coronary Heart Disease.","authors":"Woro Riyadina, Sulistyowati Tuminah, Lely Indrawati, Nikson Sitorus, Alfons M Letelay, Tri Wurisastuti, Alifa Syamantha Putri, Ika Suswanti, Yuda Turana","doi":"10.2174/0115734021346604250214071418","DOIUrl":"10.2174/0115734021346604250214071418","url":null,"abstract":"<p><p>Introduction/ Objective: Blood pressure variability (BPV) is a potential predictor of vascular events and triggers target organ damage. This study aimed to determine the BPV in stroke and coronary heart disease (CHD) in the Bogor Cohort Study in Indonesia.</p><p><strong>Methods: </strong>Over six years of monitoring, a prospective cohort study was conducted on 1649 respondents aged ≥ 31 years from the Bogor Non-communicable Diseases Risk Factors Cohort Study. The dependent variable was vascular events (stroke or CHD), which were new cases (incidents) that appeared during the 6-year monitoring period (2011 - 2017 and 2012-2018).</p><p><strong>Result: </strong>During the six years of monitoring, the incidence of vascular events was 12.4 percent. The dose-response of systolic and diastolic BPV in vascular events, stroke, and coronary heart disease showed an increased risk (quintiles Q2, Q3, and Q4) compared to quintile 1 (Q1). Systolic BPV of ≥12,10 mmHg and diastolic BPV of ≥ 7,31 mmHg had a risk of 2.3 and 1.7 (95% Confidence Intervals (CI)), respectively, for vascular events during the period of 6-year observation, after controlling for age, hypertension status, and lipid profile.</p><p><strong>Conclusion: </strong>BPV is an independent predictor of vascular events, stroke, and coronary heart disease. The public and clinicians must pay attention to controlling BPV as a risk factor for vascular events, stroke, and CHD.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"94-101"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Accuracy of 24-Hour Ambulatory Blood Pressure Monitoring <i>Versus</i> Clinic Blood Pressure for Cardiovascular and All-Cause Mortality: A Systematic Review and Meta-Analysis.","authors":"Hamidreza Soleimani, Negin S H Mohammadi, Sara M Namin, Amir Nasrollahizadeh, Tara Azardar, Kimia Najafi, Mehmet Cilingiroglu, Mushabbar Syed, Mani K Askari, Rahul Gupta, Wilbert S Aronow, Kaveh Hosseini","doi":"10.2174/0115734021337639250203175636","DOIUrl":"10.2174/0115734021337639250203175636","url":null,"abstract":"<p><strong>Introduction: </strong>According to current clinical practice guidelines, Ambulatory Blood Pressure Measurement (ABPM) is recommended to confirm diagnoses of hypertension. It remains unclear as to which method is superior in predicting mortality outcomes.</p><p><strong>Methods: </strong>Prospective observational studies, comparing ABPM with Clinical Blood Pressure Measurements (CBPM), were included with outcomes of the study being all-cause and cardiovascular mortality.</p><p><strong>Results: </strong>Nine studies with a total of 23,140 participants were included. Each 10-mmHg increase in 24-hour mean systolic blood pressure (SBP) was linked to a higher risk of all-cause mortality (HR: 1.13, 95% CI: 1.09-1.18), while Clinic Blood Pressure Measurement (CBPM) was not a significant predictor (HR: 1.02, 95% CI: 0.90-1.13). Nighttime SBP increases of 10 mmHg were associated with a higher all-cause mortality risk than daytime SBP (HR: 1.16, 95% CI: 1.11-1.21 <i>versus</i> HR: 1.08, 95% CI: 1.05-1.12). For cardiovascular mortality, a 10 mmHg increase in SBP yielded an HR of 1.21 (95% CI: 1.16-1.27) for 24-hour ABPM compared to 1.08 (95% CI: 1.04- 1.11) for CBPM. Similarly, for a 5 mmHg increase in Diastolic Blood Pressure (DBP), the HR was 1.14 (95% CI: 1.07-1.20) for 24 hour ABPM <i>versus</i> 1.04 (95% CI: 1.01-1.07) for clinical DBP, highlighting 24-hour monitoring as a stronger predictor for cardiovascular mortality.</p><p><strong>Conclusion: </strong>The findings of this study support the superiority of ABPM measurements in predicting both all-cause and cardiovascular mortality.</p>","PeriodicalId":45941,"journal":{"name":"Current Hypertension Reviews","volume":" ","pages":"102-116"},"PeriodicalIF":0.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}